KIT and metastatic neoplasm: Evaluation of stem/progenitor marker expression on cytokeratin+ cells from normal lung, untreated KIT+ and KIT- primary NSCLC, and recurrent metastatic disease presents the opportunity to correlate the presence of these markers with disease progression.